Boehringer Ingelheim Pharmaceuticals Inc. is investing $42.5 million over the next two years to build a new Safety Assessment Building on its 294-acre campus in Ridgefield and Danbury, The Danbury News-Times reports.
The building, when completed in 2013, will provide more than 63,000 square feet of space for non-clinical safety studies in development, as well as studies for research, the paper said Tuesday on its Web site.
Gov. Dannel P. Malloy, Danbury Mayor Mark Boughton and Ridgefield First Selectman Rudy Marconi were among the guests at the groundbreaking of the site Monday.
Ridgefield is home to the German pharmaceutical company’s U.S. division.
“Boehringer Ingelheim has a bright future ahead as a leader in our highly competitive industry,” said Greg Behar, president and chief executive officer of Boehringer Ingelheim Pharmaceuticals.
“This innovative $42.5 million facility has a singular purpose that is aligned with our corporate mission to bring new, innovative medicines to patients and families.”
“The fact that Boehringer Ingelheim continues to invest in its campus and create jobs is great news for Connecticut,” Malloy said. “Boehringer Ingelheim is a valued member of the Connecticut business community and a key partner in our collective efforts to strengthen the state’s bioscience industry.”
